KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors
Kiromic Biopharma (Nasdaq: KRBP) is recognized as an innovator in immuno-oncology, showcasing its AI-driven cancer targets at the 4th Annual Next-Gen Immuno Oncology Congress. The presentation focuses on artificial intelligence-selected targets, claiming enhanced safety and efficacy over conventional methods. The company plans to advance Mesothelin isoform 2 in human trials for solid tumors by Q3 2021, utilizing a CAR-T therapy with chPD1. Leadership highlights the potential of AI to significantly improve target specificity and affinity, aiming to reduce side effects and elevate treatment effectiveness.
- Recognition as a leader in immuno-oncology enhances market presence.
- AI-driven target selection could improve treatment safety and efficacy.
- Plans for first-in-human dosing of Mesothelin isoform 2 in Q3 2021 demonstrates advancement in clinical trials.
- None.
Kiromic Biopharma, Inc. (Nasdaq: KRBP)
Kiromic is being recognized as a pioneer of immuno oncology with a presentation at the 4th Annual Next-Gen Immuno Oncology Congress in June 2021.
At the conference, we will:
-- Present our artificial intelligence (AI) predicted and selected targets, and
-- Discuss how our AI targets will offer better safety and efficacy compared to immuno oncology peers with classic targets.
Our AI targets are predicted and selected based on the following characteristics:
High expression in cancer cells |
Heat map of T-cell, B-cell epitopes |
|
Low expression in normal cells |
High affinity to TCR |
|
Quantity surface antigen expression signature |
|
We intend to use our AI target, Mesothelin isoform 2, in the upcoming first-in-human dosing for solid tumors in 3Q-2021. At the first-in-human dosing, Kiromic will also introduce a CAR-T with chPD1, our PD1 activator, which will we believe offer immuno oncology with new tools to address Tumor Micro Environment (TME).
Our topics for the session on June 29th are:
-- Mesothelin isoform 2 is a novel target for allogenic CAR γδT cell therapy in solid tumors
-- Diamond Artificial Intelligence /CancerSplice : ADVANCING CAR through A.I. for Target
Link to 4th Annual Next-Gen Immuno Oncology Congress (Virtual) June-28, 2021
Chief Executive Officer of Kiromic, Maurizio Chiriva-Internati, DBSc, PhDs, commented:
"We are honored to be invited to present at the 4th Annual Next-Gen Immuno Oncology Congress.
The challenges for immuno oncology and the employment of classic targets result from low specificity, which results in higher side effects and low affinity, which results in low efficacy.
We believe our AI selected iso-mesothelin will address both of these issues.
Our selection and prediction algorithm is robust and extensive, poring over billions of data points, to arrive at these targets in hours which otherwise would have required many man-years if done manually.
We believe that the first-in-human dosing will demonstrate the safety and efficacy of our product and will also demonstrate that AI targeting is superior compared with classic targeting with immuno chemistry."
Chief Medical Officer of Kiromic, Dr. Scott Dahlbeck, commented:
"As an oncologist treating these patients and reading the data, I know first-hand about the needs in immuno oncology to address the problems of specificity and affinity in targeting.
It's very exciting for me to be part of our innovative team that is introducing AI algorithms into the search for better targets.
We are looking forward to the first in-human dosing with these AI targets in 3Q-2021."
Chief Strategy and Innovation of Kiromic, Gianluca Rotino, stated:
"The time has come for the world to see the power of AI algorithms unleashed on targets research and immuno oncology to finally get CAR-T which offers better safety and efficacy compared with classic small molecules."
------------------------------------------------------
Previous Press Release:
About Kiromic
Kiromic BioPharma, Inc. (Nasdaq: KRBP) is a target discovery and gene-editing company utilizing a state-of-the-art artificial intelligence (AI) platform focused on unleashing the power of the patient’s own immune system to fight cancer.
Kiromic’s pipeline development is leveraged through the Company’s proprietary target discovery Artificial Intelligence engine called "DIAMOND." Kiromic's DIAMOND is big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug.
Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s annual report on Form 10-K for the most recently completed fiscal year and subsequent reports filed after the date of the annual report with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and our company undertakes no duty to update such information except as required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005209/en/
FAQ
What is Kiromic Biopharma's presentation about at the 4th Annual Next-Gen Immuno Oncology Congress?
When is Kiromic Biopharma's first-in-human dosing for Mesothelin isoform 2?
What advantages does Kiromic claim their AI targets have?
Who are the key executives commenting on Kiromic's innovations?
